Text this: Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

__    __     ___      _____    __   __            
\ \\ / //   / _ \\   /  ___||  \ \\/ //     ___   
 \ \/ //   / //\ \\ | // __     \ ` //     /   || 
  \  //   |  ___  ||| \\_\ ||    | ||     | [] || 
   \//    |_||  |_|| \____//     |_||      \__ || 
    `     `-`   `-`   `---`      `-`'       -|_|| 
                                             `-`